2,568.00
-41.00 (-1.57%)
as of 2026-08-17 · marketstack
quoted in pence (GBX)
stale — last close 2026-08-17, not a live quote
Clinical trials
catalyst calendar across sponsors →Studies where IMB.L is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
7 interventional · 7 with posted results
Held by 0 tracked-famous managers · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Updated |
|---|---|---|---|---|---|---|---|
| Nicotine Pharmacokinetic Study of Heated Tobacco and Heated Herbal ProductsNCT06093659results2025-02-03Nicotine CmaxRandomized · Open-label · OtherStudy Protocol ↗ · Statistical Analysis Plan ↗ | Not applicable | Completed | Other: Heated tobacco product with heated tobacco sticks (Product A), Heated tobacco product with heated tobacco sticks (Product B), Heated herbal product with nicotine-infused heated herbal sticks (Product C), Heated herbal product with nicotine-infused heated herbal sticks (Product D), Conventional Cigarette (Product E) | Healthy Volunteers | 25 | 2023-11-03actual | 2025-02-03 |
| A Relative Bioavailability Study of Nicotine Delivery From Selected Oral Nicotine ProductsNCT05452278results2025-09-26Nicotine CmaxRandomized · Open-label · OtherStudy Protocol ↗ · Statistical Analysis Plan ↗ | Not applicable | Completed | Other: Product A, Product B, Product C, Product D | Healthy Volunteers | 27 | 2023-07-31actual | 2026-03-09 |
| A Randomised, Cross-Over, Nicotine Pharmacokinetic and Pharmacodynamic Study of Heated Tobacco Products Compared to Combustible CigarettesNCT05459857results2025-02-03Nicotine CmaxRandomized · Open-label · OtherStudy Protocol ↗ · Statistical Analysis Plan ↗ | Not applicable | Completed | Other: Product A, Product B, Product C, Product D | Healthy Volunteers | 24 | 2021-11-30actual | 2025-02-03 |
| A Randomised, Cross-over, Relative Bioavailability Study of Nicotine Delivery and Nicotine Extraction From Oral ProductsNCT04891406results2023-10-13Nicotine CmaxRandomized · Open-label · OtherStudy Protocol ↗ · Statistical Analysis Plan ↗ | Not applicable | Completed | Other: A, B, C, D, E | Healthy Volunteers | 24 | 2021-01-20actual | 2023-10-13 |
| An Exploratory PET-study of Deposition, Disposition and Brain Uptake of [11C]Nicotine After Inhalation of 2 Nicotine Formulations Via the myBluTM E-cigarette in SmokersNCT04780815results2023-05-19Lung PETNon-randomized · Open-label · OtherStudy Protocol ↗ · Statistical Analysis Plan ↗ | Not applicable | Completed | Other: myBluTM Formulation 1, myBluTM Formulation 2 | Healthy Volunteers | 16 | 2020-11-17actual | 2023-05-19 |
| A Study to Evaluate the Safety Profile of an e-Vapour ProductNCT02029196results2017-03-21Adverse EventsRandomized · Open-label · Other | Not applicable | Completed | Other: E-vapour product, Conventional cigarette | Healthy Volunteers | 408 | Nov 2016actual | 2017-03-21 |
| A Bioavailability Study of Nicotine Delivered by an Electronic Vapour ProductNCT02032212results2016-05-02Nicotine Plasma ConcentrationRandomized · Open-label · Other | Not applicable | Completed | Other: EVP unflavoured, EVP flavoured, Nicotine inhalator, Conventional cigarette | Healthy Volunteers | 12 | May 2014actual | 2025-09-10 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19